T. Meyer

Hepatology · The Lancet · 2005–2022

A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom T. Meyer trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Llovet (in Hepatology)

Papers from T. Meyer's perspective

Ordered by how strongly the researchers T. Meyer trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
  2. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. (Cancer Cell)
  3. Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
  4. [New guidelines to evaluate the response to treatment in solid tumors]. (Bulletin du Cancer)
  5. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. (Radiology)
  6. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. (Journal of Clinical Oncology)
  7. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. (Journal of Clinical Endocrinology and Metabolism)
  8. Small Bowel Cancer in the United States: Changes in Epidemiology, Treatment, and Survival Over the Last 20 Years (Annals of Surgery)
  9. Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
  10. A 5‐decade analysis of 13,715 carcinoid tumors (Cancer)

Their papers